Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (53${count})

  • Dopamine-Non-Responsive Symptoms of Parkinson's Disease, 2006
    Non-dopaminergic imaging biomarkers as tools for early PD - testing the Braak Hypothesis

    Many recent studies have suggested that we need to expand research in Parkinson's disease to study symptoms other than the typical motor symptoms of tremor, slowness of movements, stiffness, and...

  • Target Validation, 2011
    Preferential Targeting of Subpopulations of 5-HT1A Receptors

    Objective/Rationale:
    Although Parkinson's disease (PD) is primarily caused by dopamine dysfunction, function of serotonin (another neurotransmitter) is also affected. This suggests that serotonergic...

  • Developing and Validating Web-Based Clinical Assessments for, 2008
    Online Motor and Cognitive Analysis System

    Objective/Rationale:
    Despite advances in treatment approaches to Parkinson’s disease over the past 20 years, patient assessment methods have advanced little during this same period. Therefore, a...

  • Research Grant, 2021
    Bipolar Disorder and Parkinson’s Disease

    Study Rationale:
    Mood disorders are common in people with Parkinson’s disease (PD) and, in many cases, precede motor symptoms and diagnosis by years. The relationship between bipolar disorder and PD...

  • Therapeutic Pipeline Program, 2013
    Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease

    Objective/Rationale:             
    Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection.  STATegics has discovered small...

  • Cognition Biomarkers, 2013
    Assessment of Plasma Glucosylceramides and Ceramides as Biomarkers of Cognitive Impairment in Parkinson's Disease

    Objective/Rationale:
    Metabolism of the lipids glucosylceramide and ceramide is altered in Parkinson’s disease (PD). GBA mutations in this pathway, causing a build-up of glucosylceramide, increase the...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.